A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Inclusion Criteria

• Histologically confirmed diagnosis of an advanced, nonhematologic/solid tumor (with the exception of primary brain tumor).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 .
• For whom no effective standard therapy is available.
• Life expectancy of greater than or equal to (>=3) months.
• Female participants who:
• Are postmenopausal (natural amenorrhea and not due to other medical reasons) for at least 1 year before the screening visit, OR
• Are surgically sterile, OR
• If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, OR
• Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)

Male participants, even if surgically sterilized (example, status postvasectomy), who:

• Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR
• Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)
• Agree not to donate sperm during this study and for 120 days after receiving their last dose of study drug.
• Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
• Ability to swallow oral medications, willingness to undergo serial skin punch biopsies, and suitable venous access for the study-required PK and pharmacodynamic sampling.
• Clinical laboratory values as specified below within 28 days before the first dose of study drug:
• Bone marrow reserve consistent with absolute neutrophil count (ANC) >=1500 per millimeter cube (/mm˄3), platelet count >=100,000/mm˄3, and hemoglobin >=9 per gram deciliter (g/dL).
• Total bilirubin must be less than ( =3.0 g/dL.
• Serum creatinine =50 milliliter per minute (mL/minute) for participants with serum creatinine concentrations above institutional limits.
• Left ventricular ejection fraction (LVEF) greater than (>) 50 percent (%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug.
• Recovered (that is, 480 millisecond (msec), or history of congenital, long QT syndrome, or torsades de pointes).
• With any of the following blood pressure conditions:
• History of orthostatic hypotension or syncope that required medical intervention. Orthostatic hypotension is defined as a 20 millimeter of mercury (mmHg) fall in systolic blood pressure and/or a 10 mmHg fall in diastolic blood pressure within 2 to 5 minutes of quiet standing immediately after a 5-minute period of supine rest.
• Postural orthostatic tachycardia syndrome (POTS) or postural tachycardia syndrome (defined as an increase in heart rate of >30 beats per minute over baseline after 10 minutes of quiet standing).
• Hypertension that is unstable or not controlled by medication.
• Seizures requiring antiepileptic treatment.
• History of uncontrolled brain metastasis unless:
• Previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery.
• Stable disease for ≥60 days, without steroid use (or stable steroid dose established for ≥28 days before the first dose of TAK-931).
• Symptomatic and/or progressive central nervous system (CNS) metastases.
• Ongoing medical conditions, such as acute exacerbations of c